Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2012 4
2013 1
2014 5
2015 4
2016 3
2017 2
2018 1
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

17 results
Results by year
Filters applied: . Clear all
Page 1
Did you mean balanzo trial (31 results)?
Associations Between Peritoneal Glucose Exposure, Glucose Degradation Product Exposure, and Peritoneal Membrane Transport Characteristics in Peritoneal Dialysis Patients: Secondary Analysis of the balANZ Trial.
Nataatmadja MS, Johnson DW, Pascoe EM, Darssan D, Hawley CM, Cho Y; balANZ Trial Investigators. Nataatmadja MS, et al. Perit Dial Int. 2018 Sep-Oct;38(5):349-355. doi: 10.3747/pdi.2017.00223. Epub 2018 Aug 7. Perit Dial Int. 2018. PMID: 30087174 Clinical Trial.
Previous, single-center, observational cohort studies have reported conflicting findings regarding whether a relationship exists between peritoneal glucose exposure and peritoneal small solute transport rate. METHODS: In this secondary analysis of the balANZ multicenter, m …
Previous, single-center, observational cohort studies have reported conflicting findings regarding whether a relationship exists between per …
Association Between Peritoneal Glucose Exposure and Peritonitis in Peritoneal Dialysis Patients: The balANZ Trial.
Nataatmadja M, Cho Y, Pascoe EM, Darssan D, Hawley CM, Johnson DW; balANZ Trial Investigators. Nataatmadja M, et al. Perit Dial Int. 2017 Jul-Aug;37(4):407-413. doi: 10.3747/pdi.2016.00263. Epub 2017 Apr 13. Perit Dial Int. 2017. PMID: 28408714 Clinical Trial.
METHODS: In this post-hoc analysis of a multicenter, multinational, open-label randomized controlled trial of neutral pH, low-glucose degradation product (GDP) versus conventional PD solutions (balANZ trial), the relationship between peritonitis rates of low …
METHODS: In this post-hoc analysis of a multicenter, multinational, open-label randomized controlled trial of neutral pH, low-glucose …
Rationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function.
Johnson DW, Clarke M, Wilson V, Woods F, Brown FG. Johnson DW, et al. BMC Nephrol. 2010 Sep 16;11:25. doi: 10.1186/1471-2369-11-25. BMC Nephrol. 2010. PMID: 20843375 Free PMC article. Clinical Trial.
METHODS/DESIGN: Inclusion criteria are adult PD patients (CAPD or APD) aged 18-81 years whose first dialysis was within 90 days prior to or following enrolment and who have a residual GFR 5 ml/min/1.73 m2, a urine output 400 ml/day and an ability to understand the nature and requ …
METHODS/DESIGN: Inclusion criteria are adult PD patients (CAPD or APD) aged 18-81 years whose first dialysis was within 90 days prior to or …
Predictors of Residual Renal Function Decline in Peritoneal Dialysis Patients: The balANZ Trial.
Htay H, Cho Y, Pascoe EM, Darssan D, Hawley C, Johnson DW; balANZ trial investigators. Htay H, et al. Perit Dial Int. 2017 May-Jun;37(3):283-289. doi: 10.3747/pdi.2016.00206. Epub 2016 Dec 1. Perit Dial Int. 2017. PMID: 27935537 Clinical Trial.
The aim of the present study was to identify independent predictors of RRF and urine volume (UV) in incident peritoneal dialysis (PD) patients. METHODS: The study included incident PD patients who were balANZ trial participants. The primary and secondary outcomes we …
The aim of the present study was to identify independent predictors of RRF and urine volume (UV) in incident peritoneal dialysis (PD) patien …
Utility of Urinary Biomarkers in Predicting Loss of Residual Renal Function: The balANZ Trial.
Cho Y, Johnson DW, Vesey DA, Hawley CM, Clarke M, Topley N; balANZ Trial Investigators. Cho Y, et al. Perit Dial Int. 2015 Mar-Apr;35(2):159-71. doi: 10.3747/pdi.2013.00170. Epub 2014 Apr 7. Perit Dial Int. 2015. PMID: 24711637 Free PMC article. Clinical Trial.
METHODS: The study included 50 randomly selected participants from the balANZ trial who had completed 24 months of follow-up. A change in glomerular filtration rate (GFR) was used as the primary clinical outcome measure. ...
METHODS: The study included 50 randomly selected participants from the balANZ trial who had completed 24 months of follow-up. …
The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial.
Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MW, Jones B, Kulkarni H, Langham R, Ranganathan D, Schollum J, Suranyi MG, Tan SH, Voss D; balANZ Trial Investigators. Johnson DW, et al. Perit Dial Int. 2012 Sep-Oct;32(5):497-506. doi: 10.3747/pdi.2012.00052. Perit Dial Int. 2012. PMID: 22991015 Free PMC article. Clinical Trial.
BACKGROUND: A multicenter, multi-country randomized controlled trial (the balANZ study) recently reported that peritonitis rates significantly improved with the use of neutral-pH peritoneal dialysis (PD) solutions low in glucose degradation products ("biocompatible" …
BACKGROUND: A multicenter, multi-country randomized controlled trial (the balANZ study) recently reported that peritonitis rat …
The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial.
Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MW, Jones B, Kulkarni H, Langham R, Ranganathan D, Schollum J, Suranyi MG, Tan SH, Voss D; balANZ Trial Investigators. Johnson DW, et al. Nephrol Dial Transplant. 2012 Dec;27(12):4445-53. doi: 10.1093/ndt/gfs314. Epub 2012 Aug 1. Nephrol Dial Transplant. 2012. PMID: 22859794 Free PMC article. Clinical Trial.
BACKGROUND: The balANZ trial recently reported that neutral pH, low glucose degradation product (biocompatible) peritoneal dialysis (PD) solutions significantly delayed anuria and reduced peritonitis rates compared with conventional solutions. This article reports a …
BACKGROUND: The balANZ trial recently reported that neutral pH, low glucose degradation product (biocompatible) peritoneal dia …
Economic evaluation of neutral-pH, low-glucose degradation product peritoneal dialysis solutions compared with standard solutions: a secondary analysis of the balANZ Trial.
Howard K, Hayes A, Cho Y, Cass A, Clarke M, Johnson DW. Howard K, et al. Am J Kidney Dis. 2015 May;65(5):773-9. doi: 10.1053/j.ajkd.2014.12.017. Epub 2015 Mar 4. Am J Kidney Dis. 2015. PMID: 25746151 Clinical Trial.
STUDY DESIGN: Secondary economic evaluation of a randomized controlled trial. SETTING & POPULATION: 185 participants in the balANZ trial. ...Consequently, the incremental cost-effectiveness ratio also was reduced significantly: biocompatible solution beca …
STUDY DESIGN: Secondary economic evaluation of a randomized controlled trial. SETTING & POPULATION: 185 participants in the ba
Utility of serum beta-trace protein as a tool for estimating residual kidney function in peritoneal dialysis patients.
See YP, Htay H, Teixeira-Pinto A, Pascoe EM, Hawley C, Cho Y, Zhao E, Johnson DW. See YP, et al. Perit Dial Int. 2020 Aug 20:896860820945464. doi: 10.1177/0896860820945464. Online ahead of print. Perit Dial Int. 2020. PMID: 32815791
METHODS: This was a post hoc analysis of incident PD patients from the balANZ trial cohort. The outcomes evaluated were trends of serum BTP concentration with time, factors associated with change in BTP using mixed-effect multilevel linear regression and correlation …
METHODS: This was a post hoc analysis of incident PD patients from the balANZ trial cohort. The outcomes evaluated were trends …
Does the use of neutral pH, low glucose degradation product peritoneal dialysis fluids lead to better patient outcomes?
Cho Y, Johnson DW. Cho Y, et al. Curr Opin Nephrol Hypertens. 2014 Mar;23(2):192-7. doi: 10.1097/01.mnh.0000441046.13912.1f. Curr Opin Nephrol Hypertens. 2014. PMID: 24378773 Review.
PURPOSE OF REVIEW: This review will examine the impact of neutral pH, low glucose degradation product (GDP) peritoneal dialysis fluid use on patient-level clinical outcomes in peritoneal dialysis patients. RECENT FINDINGS: Recently published results from the balANZ
PURPOSE OF REVIEW: This review will examine the impact of neutral pH, low glucose degradation product (GDP) peritoneal dialysis fluid use on …
17 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback